New therapy targets toxic cholesterol byproduct in arteries
Most cardiovascular treatments lower LDL cholesterol or reduce inflammation. A new drug candidate takes a different approach, targeting a toxic cholesterol breakdown product that traps immune cells in artery walls.
Cyclarity Therapeutics has completed a Phase 1 trial with UDP-003, a compound designed to target 7-ketocholesterol (7KC). This is a byproduct of cholesterol oxidation that accumulates inside macrophages, the immune cells that patrol artery walls. When macrophages absorb too much 7KC, they become foam cells: engorged cells that can no longer perform their normal function. They contribute to the formation of hard plaques in blood vessels, one of the primary drivers of heart attack and stroke.
According to the researchers, UDP-003 is designed to convert 7KC into a form the body can excrete. This would allow foam cells to revert to functional macrophages capable of actively clearing plaque. The Phase 1 study, conducted in Australia in partnership with Monash University, focused on safety and tolerability. Results are described as successful, paving the way for further development.
Why this approach is different
Existing drugs like statins reduce the supply of cholesterol reaching the artery wall, but do not directly address damage that is already there. UDP-003 aims to reverse the local situation by neutralizing the toxic compound and restoring damaged cells. That is a conceptually different direction from most current therapies.
7-ketocholesterol also accumulates in other tissues and has been linked to aging-related changes in the eye, brain, and immune system. If the drug proves effective, applications beyond cardiovascular disease are conceivable.
What Phase 1 does and does not tell us
A successful Phase 1 trial means the compound is safe enough to test further. It says nothing yet about effectiveness in patients. Follow-up studies will need to show whether removing 7KC actually reduces plaque burden and improves outcomes in people with cardiovascular disease. The expectations are high, but the evidence still needs to arrive.
Want to research this yourself?
Search for terms like: 7-ketocholesterol atherosclerosis therapy